MAPT and supranuclear palsy, progressive, 1: The molecular binding target of 18F-AV-1451 in non-Alzheimer’s disease tauopathies is disputed; elevated ‘off-target’ binding has been demonstrated in the basal ganglia of healthy controls (Johnson et al., 2016), albeit to a lesser degree than that observed in PSP (Fig. 2F) (Passamonti et al., 2017), and in TDP-43 associated disorders without evident tau pathology (Bevan-Jones et al., 2017a).